Lung cancer is by far the most common cause of cancer death in the UK. It is a common condition, which typically presents at a late stage. Late diagnosis of lung cancer is a leading cause of poor cancer survival outcomes in the UK.
RM Partners data analysis revealed areas within west London of high incidence of lung cancer; low rates of diagnosis at the early stages of lung cancer (stages 1 and 2); high rates of diagnosis at stage 4, and low one-year survival rates for patients with lung cancer.
The RM Partners Lung Pathway Group consists of key respiratory clinicians and operational managers from north and south west London who are involved in the care and treatment of lung cancer.
The role of the group is to provide expert oversight and clinical advice to improve service delivery and patient outcomes across the Alliance for all lung cancer patients. This includes developing local strategies to improve early and faster diagnosis, identifying areas for service development or improvement, developing standards of care through multi-disciplinary team mapping, and monitoring performance of the implementation of the National Optimal Lung Cancer Pathway (NOLCP).